SOHO Annual Meeting | Conferences

September 11, 2021

Disparities not only are widening among racial groups, but socioeconomic inequities should also be considered and addressed by the wider healthcare community, according to a lymphoma expert.

September 10, 2021

Early data have shown the promise of CD19-directed chimeric antigen receptor T cells for indolent lymphoma treatment, but longer follow-up is needed to determine if these responses represent cures in these historically difficult-to-treat malignancies.

September 10, 2021

CARTITUDE-1 update shows continued deep and durable response with iltacabtagene autoleucel in patients with heavily pretreated multiple myeloma.

September 10, 2021

Rituximab with bendamustine lead to superior outcomes compared with than 2 other popular triplet therapies in patients with treatment-naïve Waldenström macroglobulinemia.

September 10, 2021

Olatoyosi Sobulo Odenike, MD, explored the risk factors for evolution to MPN AP/blast phase, outcomes for current treatment methods, and potential targeted therapies during a presentation.

September 09, 2021

IGHV and TP53 remain clinical prognostic importance in patients with chronic lymphocytic leukemia, despite many prognostic markers for chemoimmunotherapy losing their clinically relevance in the context of targeted therapies for patients.

September 09, 2021

Multiple new targets are being researched for the treatment of chronic lymphocytic leukemia, and experts a particularly excited about novel BTK inhibitors and cellular therapies.

September 09, 2021

Controlling infection in patients with chronic lymphocytic leukemia who have an increased risk for infection, may be key for improving survival rates.

September 09, 2021

Data from the phase 1/2 BRUIN clinical trial showed a 62% objective response rate with responses increasing over time.

September 09, 2021

In the REVEAL study, having high-risk polycythemia vera was associated with lower survival at 4 years compared with low-risk disease.